Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBerkeley Eng Regulatory News (BKY)

Share Price Information for Berkeley Eng (BKY)

Share Price is delayed by 15 minutes
Get Live Data
25.00    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 2.00 (8.333%)
Market Cap: £111.57m
BKY Live PriceLast checked at - London Stock Exchange

Intraday Berkeley Eng Share Chart

Permitting Update

23 Jul 2021 08:29

RNS Number : 2721G
Berkeley Energia Limited
23 July 2021
 

BERKELEY ENERGIA LIMITED

 

NEWS RELEASE | 23 July 2021

 

Permitting Update

 

Berkeley Energia Limited ("Berkeley" or the "Company") advises that it has taken the first steps to overturn the previously announced unfavorable decision by the Nuclear Safety Council ("NSC") for the grant of the Authorisation for Construction for the uranium concentrate plant as a radioactive facility ("NSC II") at the Company's Salamanca project (see announcement dated 12 July 2021).

 

Berkeley has now submitted an 'Improvement Report' to supplement the Company's initial NSC II Application, along with the corresponding arguments that address all of the issues raised by the NSC, and has requested its reassessment by the NSC. The Improvement Report includes technical arguments that, in the Company's view, will clearly demonstrate that the project is compliant with all requirements for NSC II.

 

This Improvement Report and associated documentation has been submitted to the Ministry of Ecological Transition and Demographic Challenge ("MITECO") following its notification to the Company advising that, in accordance with Spanish administrative law, a hearing process in relation to the NSC's decision has been opened and provides Berkeley with the opportunity to submit relevant documentation to MITECO by 4 August 2021.

 

As previously reported, Berkeley strongly refutes the NSC's assessment and notes that all documentation submitted by the Company in relation to NCS II has been prepared following advice from independent, nationally and internationally recognised advisors and consultants who are experts in their field.

 

It should also be noted that more than 120 previous permits and favourable reports have been granted by the relevant authorities at the local, regional, federal and European Union levels in relation to the Salamanca project, among which nine have been from the NSC.

 

The Company will continue to strongly defend its position in relation to the adverse decision by the NSC and will continue to update the market on any material developments as they occur.

 

 

For further information please contact:

Robert Behets Francisco Bellón

Acting Managing Director Chief Operations Officer

+61 8 9322 6322 +34 91 555 1380

info@berkeleyenergia.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFIFFDDRIVFIL
Date   Source Headline
31st May 20237:00 amRNSExpiry of Unlisted Options
28th Apr 20237:00 amRNSQuarterly Report March 2023
3rd Apr 202312:12 pmRNSPermitting Update
14th Mar 20237:00 amRNSHalf-year Report
7th Feb 20234:40 pmRNSSecond Price Monitoring Extn
7th Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20231:12 pmRNSPermitting Update
31st Jan 20237:00 amRNSQuarterly Report December 2022
26th Jan 20234:40 pmRNSSecond Price Monitoring Extn
26th Jan 20234:35 pmRNSPrice Monitoring Extension
3rd Jan 20237:00 amRNSExpiry of Unlisted Options
22nd Dec 20227:00 amRNSReport on Payments to Governments
1st Dec 20227:00 amRNSUnlisted Options
18th Nov 20227:00 amRNSNotification of Investment Dispute
15th Nov 20227:00 amRNSResult of AGM
9th Nov 20227:00 amRNSBerkeley establishes Spanish Advisory Committee
27th Oct 20227:00 amRNSQuarterly Report September 2022
20th Oct 20222:13 pmRNSPublication of a Prospectus
4th Oct 20227:00 amRNSNotice of AGM
23rd Sep 20224:35 pmRNSPrice Monitoring Extension
19th Sep 20227:45 amRNSDate of AGM
31st Aug 202210:00 amRNS2022 Annual Report
29th Jul 20227:00 amRNSQuarterly Report June 2022
5th Jul 20227:00 amRNSChange of Director’s Interest Notice
28th Jun 20227:00 amRNSStrengthening of Board with Spanish Based Director
29th Apr 20227:00 amRNSQuarterly Report March 2022
29th Apr 20227:00 amRNSQuarterly Report March 2022
5th Apr 20228:46 amRNSNotice of Initial Substantial Holder
5th Apr 20227:00 amRNSNotice of Initial Substantial Holder
1st Apr 20227:00 amRNSSettlement of OIA Claim
24th Mar 20224:36 pmRNSPrice Monitoring Extension
24th Mar 20222:00 pmRNSPrice Monitoring Extension
24th Mar 202211:05 amRNSSecond Price Monitoring Extn
24th Mar 202211:00 amRNSPrice Monitoring Extension
21st Mar 20224:42 pmRNSSecond Price Monitoring Extn
21st Mar 20224:35 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSResponse to ASX Price and Volume Query
16th Mar 20222:06 pmRNSSecond Price Monitoring Extn
16th Mar 20222:00 pmRNSPrice Monitoring Extension
16th Mar 202211:06 amRNSSecond Price Monitoring Extn
16th Mar 202211:00 amRNSPrice Monitoring Extension
15th Mar 20227:00 amRNSHalf-year Report
14th Mar 20224:40 pmRNSSecond Price Monitoring Extn
14th Mar 20224:35 pmRNSPrice Monitoring Extension
14th Mar 20222:06 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 202211:05 amRNSSecond Price Monitoring Extn
14th Mar 202211:00 amRNSPrice Monitoring Extension
31st Jan 20227:00 amRNSQuarterly Report December 2021
4th Jan 20229:06 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.